Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886773 | 1.00 | GCK (0.61) | GCK | |
| SCHEMBL885426 | 0.91 | GCK (0.63) | GCK | |
| SCHEMBL886788 | 0.91 | GCK (0.63) | GCK | |
| SCHEMBL886779 | 0.90 | GCK (0.57) | GCK | |
| SCHEMBL886778 | 0.90 | GCK (0.57) | GCK | |
| SCHEMBL883967 | 0.89 | GCK (0.60) | GCK | |
| SCHEMBL883969 | 0.89 | GCK (0.60) | GCK | |
| SCHEMBL884412 | 0.88 | GCK (0.59) | GCK | |
| SCHEMBL884413 | 0.88 | GCK (0.59) | GCK | |
| SCHEMBL1930468 | 0.88 | GCK (0.67) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148412-B2 | e.g. {-[3-Cyclopentyl-2-(4-methane sulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester; antidiabetic and hypoglycemic agent; non-insulin dependent diabetis, obesity, impaired glucose tolerance, eating disorder, dyslipidemia, hyperlipidemia, hypertension | NOVO NORDISK A/S (DK) | 2012-04-03 | — | — | US | claimed |
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-06-12 | — | — | US | claimed |
| EP-1824835-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-08-29 | — | — | EP | claimed |
| WO-2006058923-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-06-08 | — | — | WO | claimed |
| US-8148412-B2 | e.g. {-[3-Cyclopentyl-2-(4-methane sulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester; antidiabetic and hypoglycemic agent; non-insulin dependent diabetis, obesity, impaired glucose tolerance, eating disorder, dyslipidemia, hyperlipidemia, hypertension | NOVO NORDISK A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-8148412-B2 | e.g. {-[3-Cyclopentyl-2-(4-methane sulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester; antidiabetic and hypoglycemic agent; non-insulin dependent diabetis, obesity, impaired glucose tolerance, eating disorder, dyslipidemia, hyperlipidemia, hypertension | NOVO NORDISK A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-8148412-B2 | e.g. {-[3-Cyclopentyl-2-(4-methane sulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester; antidiabetic and hypoglycemic agent; non-insulin dependent diabetis, obesity, impaired glucose tolerance, eating disorder, dyslipidemia, hyperlipidemia, hypertension | NOVO NORDISK A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| EP-1824835-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006058923-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006058923-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | GCK, GCKR, PDXK | GCK 1/4885 |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.